Thomas’ announces flavor of the year
HORSHAM, Pa. — The Thomas’ brand, a creator and baker of English Muffins, introduced it’s flavor of the year: Cinnamon Vanilla. This is the only new flavor the company will offer in 2014.
Thomas’ Cinnamon Vanilla English Muffins take inspiration from fresh cinnamon buns and provide the same sweet scent and flavor for 150 calories, the company said. The flavor is part of Thomas’ new Limited Edition line, which will include different seasonal flavors every three months: Cinnamon Vanilla English Muffins and Maple French Toast Bagels (through July 2014); Apple Pie English Muffins and Bagels (July through October 2014); and Cranberry English Muffins and Bagels (October through December 2014).
“People often rush to make and eat breakfast, and we wanted to give them more reasons to slow down and enjoy,” said Alicia Rosas, Category Director, Thomas’ Bagels. “We all know how satisfying it is to smell delicious baked goods, so when developing our new Limited Edition line, it was important that the aroma was just as sweet and enticing as the taste.”
The Limited Edition Cinnamon Vanilla English Muffins and Maple French Toast Bagels are now available natiowinde and can be found in mass retail stores for a suggested retail price between $3.99 to $4.69.
Cracker Jack’D announces new trail mix
PLANO, TX — Cracker Jack’D, a brand from Frito-Lay, announced the addition of Energy Trail Mixes to its line of products. The snack, available in Chocolate Flavored Cherry and Mixed Berry, will hit shelves this month.
The new trail mixes include a unique packaging structure that hold fruit bits in a separate pouch within the larger package, which helps to keep them tasting fresh while also ensuring that the granola and nuts stay crunchy. The seasoned mixed snack is ideal for young adults on the go, the company said.
Cracker Jack’D Energy Trail Mixes can be found in 4.5-5-oz. bags for a suggested retail price of $3.79.
Pfizer confirms merger discussions with AstraZeneca
NEW YORK — U.S. pharmaceutical firm Pfizer this morning confirmed discussions with AstraZeneca regarding a possible merger. If the transaction goes through, it’s expected that the two companies will combine under a new U.K-incorporated holding company.
Pfizer said it would expect the combined company to have management in both the United States and the United Kingdom, with head offices in New York. AstraZeneca was approached in January 2014 regarding a possible merger, but the company declined to continue with negotiations at that time.
“We have great respect for AstraZeneca and its proud heritage as an innovation-driven biopharmaceutical business with a rich science-based foundation in both the United Kingdom and Sweden. In addition, the United Kingdom has created attractive incentives for companies to manufacture products and maintain and protect intellectual property, and we have seen that capital and jobs have followed these types of incentives," Pfizer said. "“We believe patients all over the globe would benefit from our shared commitment to R&D, which is critical to the future success of the pharmaceutical industry, in the form of potential new therapies that help to fight some of the world’s most feared diseases, such as cancer."